

Supplemental Data: Tables e-1 and e-2

Table e-1 Baseline characteristics of the ITT study population

	EGCG (n = 30)	Placebo (n = 31)
Age (years)	49.50 (7.70)	48.84 (7.56)
Women	14 (46.7%)	13 (41.9%)
EDSS	6.0 (3.0-8.0) 5.5 (1.3)	6.0 (3.0-7.0) 5.29 (1.2)
PPMS	11 (36.7%)	12 (38.7%)
SPMS	19 (63.3%)	19 (61.3%)
Disease duration (years)	11.08 (8.98)	9.42 (6.18)
Duration of progression (years)	6.48 (5.13)	5.05 (3.66)
MSFC Z-score	0.15 (0.58)	0.01 (0.64)
PASAT	43.30 (11.90)	42.23 (12.53)
TWT average speed (s)	12.65 (8.74)	11.72 (11.73)
9-HPT (s) average	30.53 (14.25)	30.90 (9.95)
BPF	0.7067 (0.0571)	0.7008 (0.0415)
CEL count	0.25 (0.52) ¹	0.48 (2.00) ²
CEL volume (ml)	0.05 (0.17) ¹	0.02 (0.07) ²
T2w lesion count	41.30 (22.29)	44.19 (26.97)
T2w lesion volume (ml)	18.42 (17.07)	15.64 (14.46)

Data are mean (SD), median (range) or number (%).¹ Data available for 28 patients, ² Data available for 25 patients.

Abbreviations: ITT = Intention to treat, CEL = Contrast enhancing lesions, PPMS = Primary progressive Multiple Sclerosis, SPMS = Secondary progressive Multiple Sclerosis, MSFC = Multiple Sclerosis Functional Composite, PASAT = Paced Auditory Serial Addition Test, BPF = Brain parenchymal fraction, EGCG = epigallocatechin-3-gallate, EDSS = Expanded Disability Status Scale, FSS = Fatigue Severity Scale, MFIS = Modified Fatigue Impact Scale, BDI = Beck Depression Inventory, 9-HPT = 9-Hole-Peg Test. TWT = Timed 25-Foot Walk Test.

Table e-2 Adverse Events for the randomized phase

	EGCG (n = 30)	Placebo (n = 31)	<i>p</i> -value
Number of patients with any adverse event	29 (96.7%)	28 (90.3%)	
Number of adverse events	155	155	
Cause of most common adverse events (> 3% per group)			
Flu-like infection	24 (15.6%)	13 (8.4%)	0.099
Fracture after fall	5 (3.3%)	5 (3.3%)	1.000
Contusion after fall	11 (7.1%)	3 (1.9%)	0.057
Pain	2 (1.3%)	8 (5.2%)	0.109
Urinary tract infection	5 (3.3%)	6 (3.9%)	1.000
Respiratory infection	2 (1.3%)	5 (3.3%)	0.453
GPT elevation	6 (3.9%)	4 (2.6%)	0.754
GOT elevation	5 (3.3%)	2 (1.3%)	0.453
Number of patients with serious adverse event	11 (36.7%)	10 (32.3%)	
Number of serious adverse events	17	11	
Cause of serious adverse events			
Fracture Weber B	1		
Serial rib fracture		1	
Fall with headache	1		
Micturition dysfunction	2		
Fracture ankle joint	1		
Benign paroxysmal positional vertigo		1	
In-patient rehabilitation (due to multiple sclerosis)		1	

Injection abscess		1
Seizure	1	
Pelvic fracture	1	
Parkinson disease	3	
Somatisation disorder in depression	3	
Filiform ACI stenosis	1	
Multilocular pain syndrome	2	
AV block 3rd degree		1
Pain right flank		1
Fracture lower leg		1
Femur fracture		1
Removal of material after femur fracture		1
Incrusted permanent suprapubic catheter		1
Stroke		1
Bronchopneumonia	1	

Data are numbers (%). Abbreviations: EGCG = epigallocatechin-3-gallate.